TY - JOUR
T1 - Intraoperative Cell Salvage During Radical Cystectomy Does Not Affect Long-Term Survival
AU - Nieder, Alan M.
AU - Manoharan, Murugesan
AU - Yang, Yulong
AU - Soloway, Mark S.
PY - 2007/5/1
Y1 - 2007/5/1
N2 - Objectives: To evaluate the risk of long-term recurrence for patients who received cell-salvaged blood during radical cystectomy (RC). Methods: We retrospectively analyzed an RC database and compared those who did and did not receive cell-salvaged blood according to baseline parameters, pathologic outcomes, and recurrence. Results: A total of 378 patients underwent RC between 1992 and 2005 by one surgeon. Of these, 65 (17.2%) received cell-salvaged blood and 313 (82.8%) did not. The two groups had similar baseline characteristics. There were no differences between the two groups when compared by pathologic stage. The median follow-up for patients who did and did not receive cell-salvaged blood was 19.1 and 20.7 months, respectively (P = 0.464). The 3-year disease-specific survival rate for the two groups was 72.2% and 73.0%, respectively (P = 0.90). Conclusions: Intraoperative cell salvage is a safe blood management strategy for patients undergoing RC. There is no increased risk of metastatic disease or death for those who receive cell-salvaged blood. Concerns about spreading tumors cells by IOCS during RC would seem unwarranted. However, only a prospective, multicenter, randomized trial would provide the most valid assessment of the safety of IOCS.
AB - Objectives: To evaluate the risk of long-term recurrence for patients who received cell-salvaged blood during radical cystectomy (RC). Methods: We retrospectively analyzed an RC database and compared those who did and did not receive cell-salvaged blood according to baseline parameters, pathologic outcomes, and recurrence. Results: A total of 378 patients underwent RC between 1992 and 2005 by one surgeon. Of these, 65 (17.2%) received cell-salvaged blood and 313 (82.8%) did not. The two groups had similar baseline characteristics. There were no differences between the two groups when compared by pathologic stage. The median follow-up for patients who did and did not receive cell-salvaged blood was 19.1 and 20.7 months, respectively (P = 0.464). The 3-year disease-specific survival rate for the two groups was 72.2% and 73.0%, respectively (P = 0.90). Conclusions: Intraoperative cell salvage is a safe blood management strategy for patients undergoing RC. There is no increased risk of metastatic disease or death for those who receive cell-salvaged blood. Concerns about spreading tumors cells by IOCS during RC would seem unwarranted. However, only a prospective, multicenter, randomized trial would provide the most valid assessment of the safety of IOCS.
UR - http://www.scopus.com/inward/record.url?scp=34247598300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247598300&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2007.01.060
DO - 10.1016/j.urology.2007.01.060
M3 - Article
C2 - 17482926
AN - SCOPUS:34247598300
VL - 69
SP - 881
EP - 884
JO - Urology
JF - Urology
SN - 0090-4295
IS - 5
ER -